Oncocyte Stock News

OncoCyte Corporation (NASDAQ:OCX) price on Friday, December 10, fall -6.28% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.24. A look at the stocks price movement, the close in the last trading session was $2.39, moving within a range at $2.20 and $2.669. The beta value (5-Year Thinking Of Buying OncoCyte Corporation (NASDAQ: OCX) Stock? Heres What You Need To Know Read More »

Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer

Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer DetermaIO shown to work across multiple platforms, including PCR and NGS, with the potential to be used for pan-cancer diagnostic testing worldwide Oncocyte supported a Continuing Medical Education event on Immunotherapy Biomarkers at SABCS, hosting key opinion leaders from the United States and Europe IRVINE, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ: OCX ), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced results showing the ability of the Company''s DetermaIO test, a commercially-available precision diagnostic designed to determine the likelihood of response to immunotherapies (IO), at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).

Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit

OncoCyte's (OCX) CEO Ronnie Andrews on Q3 2021 Results - Earnings Call Transcript

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear ins

Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient's response to immunotherapy Data show that DetermaIO demonstrates superior accur

Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response

CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights

IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear in

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

Oncocyte Corporation's (NASDAQ: OCX) Q2 revenues were $2.03 million, compared to $143,000 in Q2 FY20 and beating consensus of $1.57 million. Most revenues were attributable to tech transfer under a

Oncocyte Corporation (OCX) CEO Ronnie Andrews on Q2 2021 Results - Earnings Call Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of 0.00% and 23.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?